Skin News and Research

RSS

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe’s proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).

10 Sep 2009

New treatment for facial wrinkles combines high-intensity light and green tea extract lotion

Scientists in Germany are reporting a major improvement in their potential new treatment for facial wrinkles that could emerge as an alternative to Botox and cosmetic surgery. The non-invasive technique combines high-intensity light from light-emitting diodes (LEDs) and a lotion made of green tea extract. It works ten times faster than a similar anti-wrinkle treatment that uses LEDs alone, the researchers say.

10 Sep 2009

Virginia Tech wins National Science Foundation grant to study knee ligament sprains

A team of Virginia Tech engineering researchers has won a $300,000 National Science Foundation grant to study knee ligament sprains at the micro-mechanical level.

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

Medpro completes preliminary testing and regulatory requirements for its VACUETTE safety needle system

MedPro Safety Products, Inc. (OTCBB: MPSP), a pioneer in the development and marketing of passive needlestick injury prevention technology, announced today it has completed preliminary testing and regulatory requirements for the VACUETTE® PREMIUM Safety Needle System Tube-Touch model, a single-patient, multiple sample blood collection safety needle system.

9 Sep 2009

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

The first-ever New Jersey Psoriasis Walk will take place in Paramus this Saturday, September 12, 2009, at beautiful Van Saun Park. The walk, to support the research and education programs of the nonprofit Psoriasis Cure Now, will include entertainment, information booths on psoriasis treatments, and a chance to meet and learn from others living with psoriasis and psoriatic arthritis. Janine Natoli of Little Falls is volunteer Chair of the NJ Psoriasis Walk, on the Web at http://www.PsoriasisWalkNJ.org.

9 Sep 2009

Moisturizing skin helps manage Keratosis Pilaris

KP is a genetic skin condition that affects 40 percent of the world's population, often resulting in patches of dry skin, and little red bumps, on the arms and legs. KP is most prevalent in the teenage years but may continue throughout adulthood. There is no cure for Keratosis Pilaris.

9 Sep 2009

Research reveals new protective properties of vitamin C

Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration.

9 Sep 2009

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

9 Sep 2009

New procedure used for breast cancer surgery

Breast cancer surgeons and radiation oncologists at St. Joseph Hospital in Orange performed a new procedure combining removal of a patient’s breast tumor with the power of electron beam radiation in the operating room.

8 Sep 2009

Scientists use advanced technology to find about composite structure of skin

Leeds scientists are using the most sophisticated techniques to tackle a question almost as old as mankind itself - what makes skin feel good, and why?

8 Sep 2009

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.

8 Sep 2009

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

8 Sep 2009

FDA undecided on safety guidelines for hydroquinone use

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

8 Sep 2009

Increased public awareness of cancer symptoms necessary to prevent avoidable deaths

One in seven people cannot name a single symptom of cancer, according to a Cancer Research UK survey published today (Monday).

8 Sep 2009

Household sun exposure in the UK increases skin cancer prevalence

More than 50 per cent of people who suffered sunburn last summer were burnt while at home in the UK, according to a Cancer Research UK survey released today as Bank Holiday temperatures are expected to soar.

8 Sep 2009

Presence of virus linked with malignant human prostate cancer cells

In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers at the University of Utah and Columbia University medical schools have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells.

7 Sep 2009

Skin News and Research

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

NovaBay begins clinical studies for treating impetigo skin infection

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

New treatment for facial wrinkles combines high-intensity light and green tea extract lotion

Virginia Tech wins National Science Foundation grant to study knee ligament sprains

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

Medpro completes preliminary testing and regulatory requirements for its VACUETTE safety needle system

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

Moisturizing skin helps manage Keratosis Pilaris

Research reveals new protective properties of vitamin C

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

New procedure used for breast cancer surgery

Scientists use advanced technology to find about composite structure of skin

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

FDA undecided on safety guidelines for hydroquinone use

Increased public awareness of cancer symptoms necessary to prevent avoidable deaths

Household sun exposure in the UK increases skin cancer prevalence

Presence of virus linked with malignant human prostate cancer cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News